Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Vanda Pharmaceuticals Inc. (VNDA)
NASDAQ:VNDA
VNDA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.71 - $6.75
Previous CloseN/A
Volume240.10K
Average Volume (3M)654.27K
Market Cap
$260.09M
Enterprise Value-$95.07M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.40
Next Earnings
Apr 30, 2025EPS Estimate
-0.57Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.33
Shares Outstanding58,316,044
10 Day Avg. Volume781,604
30 Day Avg. Volume654,272
Standard Deviation0.12
R-Squared0.10
Alpha-0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.36
Price to Cash Flow (P/CF)-4.50
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.37
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.48
Enterprise Value/Ebitda2.92
Forecast
1Y Price Target
$16.50Price Target Upside267.48% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Vanda News
PremiumCompany Announcements
Vanda Sets 2025 Executive Compensation Plans---
Bulls Say, Bears Say
Bulls Say
Market ResponseSeveral lead indicators suggest a strong initial market response to Fanapt for acute treatment of bipolar I disorder in adults, including new patient starts as reflected by new to brand prescriptions (NBRx), increasing by >90% in 3Q24 vs. 3Q23.
Regulatory ApprovalRegulatory approval for tradipitant could drive meaningful upside to forecasts, as its sales are not currently included in the valuation assessment.
Bears Say
Regulatory ChallengesThe FDA plans to reject the tradipitant NDA due to failure to demonstrate compelling evidence of efficacy in pivotal trials for symptom relief in gastroparesis.
---
Ownership Overview
5.30% Insiders
17.55% Mutual Funds
9.91% Other Institutional Investors
53.09% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
VNDA FAQ
What was Vanda Pharmaceuticals Inc.’s price range in the past 12 months?
Vanda Pharmaceuticals Inc. lowest stock price was $3.71 and its highest was $6.75 in the past 12 months.
What is Vanda Pharmaceuticals Inc.’s market cap?
Vanda Pharmaceuticals Inc.’s market cap is $260.09M.
When is Vanda Pharmaceuticals Inc.’s upcoming earnings report date?
Vanda Pharmaceuticals Inc.’s upcoming earnings report date is Apr 30, 2025 which is in 67 days.
How were Vanda Pharmaceuticals Inc.’s earnings last quarter?
Vanda Pharmaceuticals Inc. released its earnings results on Feb 13, 2025. The company reported -$0.08 earnings per share for the quarter, beating the consensus estimate of -$0.107 by $0.027.
Is Vanda Pharmaceuticals Inc. overvalued?
According to Wall Street analysts Vanda Pharmaceuticals Inc.’s price is currently Undervalued.
Does Vanda Pharmaceuticals Inc. pay dividends?
Vanda Pharmaceuticals Inc. does not currently pay dividends.
What is Vanda Pharmaceuticals Inc.’s EPS estimate?
Vanda Pharmaceuticals Inc.’s EPS estimate is -0.57.
How many shares outstanding does Vanda Pharmaceuticals Inc. have?
Vanda Pharmaceuticals Inc. has 58,316,044 shares outstanding.
What happened to Vanda Pharmaceuticals Inc.’s price movement after its last earnings report?
Vanda Pharmaceuticals Inc. reported an EPS of -$0.08 in its last earnings report, beating expectations of -$0.107. Following the earnings report the stock price went down -5.957%.
Which hedge fund is a major shareholder of Vanda Pharmaceuticals Inc.?
Currently, no hedge funds are holding shares in VNDA
---
Vanda Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$16.50 (267.48% Upside)
$16.50 (267.48% Upside)
Blogger Sentiment
Bullish
VNDA Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 27.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $25.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.8%
Last 30 Days ▼ 0.8%
Last 30 Days ▼ 0.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
3.88%
12-Months-Change
Fundamentals
Return on Equity
-3.49%
Trailing 12-Months
Asset Growth
1.20%
Trailing 12-Months
Company Description
Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.
---
VNDA Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed outlook, with significant revenue growth from Fanapt and successful integration of Ponvory, countered by a substantial decline in Hetlioz sales due to generic competition and increased net losses. The company's robust pipeline and strategic initiatives suggest potential for future growth, but operational and regulatory challenges raise concerns.Read More>---
VNDA Stock 12 Month Forecast
Average Price Target
$16.50
▲(267.48% Upside)
Technical Analysis
ACADIA Pharmaceuticals
―
Neurocrine
―
Supernus Pharmaceuticals
―
Intra-Cellular Therapies
―
Axsome Therapeutics
―
Best Analysts Covering VNDA
1 Year
1 Year Success Rate
1/6 ratings generated profit
1 Year Average Return
-13.25%
reiterated a buy rating 8 days ago
Copying Charles Duncan's trades and holding each position for 1 Year would result in 16.67% of your transactions generating a profit, with an average return of -13.25% per trade.
---